# Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension

> **NCT00498433** · PHASE2 · TERMINATED · sponsor: **Novartis** · enrollment: 46 (actual)

## Conditions studied

- Hypertension
- Abdominal Obesity

## Interventions

- **DRUG:** Aliskiren
- **DRUG:** Amlodipine
- **DRUG:** Placebo of Aliskiren
- **DRUG:** Placebo of amlodipine

## Key facts

- **NCT ID:** NCT00498433
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-06
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 46 (ACTUAL)
- **Why stopped:** Early termination resulted from interim analysis of the ALTITUDE trial
- **Last updated:** 2014-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00498433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00498433, "Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT00498433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*